Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor agonist peptide, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC heterozygous deficiency obesity and POMC epigenetic disorders. It is also developing RM-853, an orally available ghrelin o-acyltransferase inhibitor that is in preclinical development for Prader-Willi syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone857-264-4280
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees54
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
Rhythm Pharmaceuticals (NASDAQ:RYTM) Frequently Asked Questions
What is Rhythm Pharmaceuticals' stock symbol?
Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."
How were Rhythm Pharmaceuticals' earnings last quarter?
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) posted its quarterly earnings results on Friday, May, 3rd. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by $0.08. View Rhythm Pharmaceuticals' Earnings History.
When is Rhythm Pharmaceuticals' next earnings date?
What price target have analysts set for RYTM?
5 equities research analysts have issued 1 year target prices for Rhythm Pharmaceuticals' shares. Their predictions range from $34.00 to $43.00. On average, they anticipate Rhythm Pharmaceuticals' share price to reach $39.40 in the next twelve months. This suggests a possible upside of 51.5% from the stock's current price. View Analyst Price Targets for Rhythm Pharmaceuticals.
What is the consensus analysts' recommendation for Rhythm Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rhythm Pharmaceuticals.
What are Wall Street analysts saying about Rhythm Pharmaceuticals stock?
Here are some recent quotes from research analysts about Rhythm Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide, a potent, first-in-class melanocortin-4 receptor or MC4R, agonist for the treatment of rare genetic disorders of obesity. Rhythm Pharmaceuticals, Inc. is based in Boston, MA. " (5/17/2019)
- 2. Needham & Company LLC analysts commented, "Rhythm reported 1Q19 financial results today and we spoke w/ mgmt for an update. Top-line results from setmelanotide Phase 3 trials in POMC and LEPR are expected 3Q19. We continue to expect positive outcomes based on impressive Phase 2 data. Rhythm is still opening sites in the setmelanotide Phase 3 trial in pts w/ but mgmt reiterated guidance for completing enrollment in 2H19 and results in 2H20. The company is assessing 6-12 other rare genetic obesity disorders for potential inclusion in the ongoing Phase 2 basket trial. An update is expected later this yr. Mgmt also plans to share more data from GO-ID obesity DNA sequencing study and TEMPO rare genetic obesity registry later this yr. BUY." (5/5/2019)
- 3. Stifel Nicolaus analysts commented, "We update our model accordingly. Overall, our thesis remains unchanged and while we continue to model a high POS for setmelanotide as a treatment for rare genetic obesity disorders, we feel this is largely factored into the stock, and ultimately the lack of near-term catalysts and questions around the size of the commercial opportunity for POMC and LepR deficiency obesities keeps us on the sidelines for now. The company continues to make good progress in its setmelanotide Phase 3 programs and we think any incremental updates on the status of its TEMPO registry efforts to identify patients with genetic obesities, particularly ones which could be treated with setmelanotide, could prove to be positive catalysts if it looks like the prevalence of these disorders are greater than clinical epidemiology/literature has shown. We maintain our Hold rating and $36 target price." (11/11/2018)
Has Rhythm Pharmaceuticals been receiving favorable news coverage?
News headlines about RYTM stock have been trending positive recently, according to InfoTrie. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Rhythm Pharmaceuticals earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days.
Who are some of Rhythm Pharmaceuticals' key competitors?
Some companies that are related to Rhythm Pharmaceuticals include HUTCHISON CHINA/S (HCM), Global Blood Therapeutics (GBT), Ultragenyx Pharmaceutical (RARE), FibroGen (FGEN), Agios Pharmaceuticals (AGIO), Amicus Therapeutics (FOLD), Mirati Therapeutics (MRTX), Biohaven Pharmaceutical (BHVN), Arena Pharmaceuticals (ARNA), Reata Pharmaceuticals (RETA), Intercept Pharmaceuticals (ICPT), The Medicines (MDCO), Amneal Pharmaceuticals (AMRX), Uniqure (QURE) and PTC Therapeutics (PTCT).
What other stocks do shareholders of Rhythm Pharmaceuticals own?
Who are Rhythm Pharmaceuticals' key executives?
Rhythm Pharmaceuticals' management team includes the folowing people:
- Dr. Keith Michael Gottesdiener, Pres, CEO & Director (Age 65)
- Mr. Hunter C. Smith, CFO & Treasurer (Age 50)
- Ms. Nithya Desikan, Chief Commercial Officer (Age 40)
- Mr. Leonardus H.T. van der Ploeg, Chief Scientific Officer (Age 64)
- Mr. Simon D. Kelner, Chief HR Officer (Age 46)
When did Rhythm Pharmaceuticals IPO?
(RYTM) raised $100 million in an initial public offering (IPO) on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager.
Who are Rhythm Pharmaceuticals' major shareholders?
Rhythm Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (9.54%), TRV GP LLC (5.76%), FMR LLC (4.62%), BlackRock Inc. (4.44%), Federated Investors Inc. PA (2.59%) and TimesSquare Capital Management LLC (2.15%). Company insiders that own Rhythm Pharmaceuticals stock include Bros Advisors Lp Baker, David P Meeker, Der Ploeg Leonardus HT Van, James E Flynn, Keith Michael Gottesdiener, Orbimed Advisors Llc and SA Ipsen. View Institutional Ownership Trends for Rhythm Pharmaceuticals.
Which major investors are selling Rhythm Pharmaceuticals stock?
RYTM stock was sold by a variety of institutional investors in the last quarter, including TRV GP LLC, FMR LLC, Citigroup Inc., BlackRock Inc., Wellington Management Group LLP, Morgan Stanley, TimesSquare Capital Management LLC and Perceptive Advisors LLC. Company insiders that have sold Rhythm Pharmaceuticals company stock in the last year include Der Ploeg Leonardus HT Van and Keith Michael Gottesdiener. View Insider Buying and Selling for Rhythm Pharmaceuticals.
Which major investors are buying Rhythm Pharmaceuticals stock?
RYTM stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Spark Investment Management LLC, Hamilton Lane Advisors LLC, ArrowMark Colorado Holdings LLC, Rice Hall James & Associates LLC, ExodusPoint Capital Management LP, Janus Henderson Group PLC and Geode Capital Management LLC. Company insiders that have bought Rhythm Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, David P Meeker, James E Flynn and SA Ipsen. View Insider Buying and Selling for Rhythm Pharmaceuticals.
How do I buy shares of Rhythm Pharmaceuticals?
Shares of RYTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Rhythm Pharmaceuticals' stock price today?
One share of RYTM stock can currently be purchased for approximately $26.00.
How big of a company is Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals has a market capitalization of $895.23 million. The company earns $-74,060,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis. Rhythm Pharmaceuticals employs 54 workers across the globe.
What is Rhythm Pharmaceuticals' official website?
How can I contact Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals' mailing address is 500 BOYLSTON STREET 11TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-264-4280 or via email at [email protected]
MarketBeat Community Rating for Rhythm Pharmaceuticals (NASDAQ RYTM)
MarketBeat's community ratings are surveys of what our community members think about Rhythm Pharmaceuticals and other stocks. Vote "Outperform" if you believe RYTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RYTM will underperform the S&P 500 over the long term. You may vote once every thirty days.
